GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Interpace Biosciences Inc (OTCPK:IDXG) » Definitions » Cyclically Adjusted Price-to-FCF

Interpace Biosciences (Interpace Biosciences) Cyclically Adjusted Price-to-FCF : (As of May. 17, 2024)


View and export this data going back to 1998. Start your Free Trial

What is Interpace Biosciences Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


Interpace Biosciences Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Interpace Biosciences's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Interpace Biosciences Cyclically Adjusted Price-to-FCF Chart

Interpace Biosciences Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Interpace Biosciences Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Interpace Biosciences's Cyclically Adjusted Price-to-FCF

For the Diagnostics & Research subindustry, Interpace Biosciences's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Interpace Biosciences's Cyclically Adjusted Price-to-FCF Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Interpace Biosciences's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Interpace Biosciences's Cyclically Adjusted Price-to-FCF falls into.



Interpace Biosciences Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Interpace Biosciences's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Interpace Biosciences's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2024 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-0.02/131.7762*131.7762
=-0.020

Current CPI (Mar. 2024) = 131.7762.

Interpace Biosciences Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201406 -14.570 100.560 -19.093
201409 -57.826 100.428 -75.876
201412 -66.879 99.070 -88.958
201503 -40.540 99.621 -53.625
201506 -17.112 100.684 -22.396
201509 -34.631 100.392 -45.457
201512 -37.975 99.792 -50.146
201603 -22.303 100.470 -29.252
201606 -7.148 101.688 -9.263
201609 -7.396 101.861 -9.568
201612 -5.323 101.863 -6.886
201703 -9.473 102.862 -12.136
201706 -4.579 103.349 -5.838
201709 -1.957 104.136 -2.476
201712 -0.855 104.011 -1.083
201803 -0.917 105.290 -1.148
201806 -0.914 106.317 -1.133
201809 -0.738 106.507 -0.913
201812 -0.676 105.998 -0.840
201903 -0.846 107.251 -1.039
201906 -1.275 108.070 -1.555
201909 -1.264 108.329 -1.538
201912 -1.677 108.420 -2.038
202003 -1.779 108.902 -2.153
202006 0.111 108.767 0.134
202009 -1.417 109.815 -1.700
202012 -0.392 109.897 -0.470
202103 -1.224 111.754 -1.443
202106 -0.443 114.631 -0.509
202109 -0.162 115.734 -0.184
202112 -0.291 117.630 -0.326
202203 -0.303 121.301 -0.329
202206 -0.706 125.017 -0.744
202209 -0.774 125.227 -0.814
202212 -0.111 125.222 -0.117
202303 0.248 127.348 0.257
202306 0.070 128.729 0.072
202309 0.000 129.860 0.000
202312 0.227 129.419 0.231
202403 -0.020 131.776 -0.020

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Interpace Biosciences  (OTCPK:IDXG) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Interpace Biosciences Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Interpace Biosciences's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Interpace Biosciences (Interpace Biosciences) Business Description

Traded in Other Exchanges
Address
300 Interpace Parkway, Morris Corporate Center 1, Building C, Parsippany, NJ, USA, 07054
Interpace Biosciences Inc is engaged in the life sciences industry. It provides molecular diagnostics, bioinformatics, and pathology services for the evaluation of the risk of cancer by leveraging the latest technology in personalized medicine for improved patient diagnosis and management. The company develops and commercializes genomic tests and related first-line assays principally focused on the early detection of patients with indeterminate biopsies and at high risk of cancer using the latest technology. It operates under one segment which is the business of developing and selling diagnostic clinical services.
Executives
Christopher Mccarthy officer: Principal Financial Officer C/O INTERPACE BIOSCIENCES, INC., 300 INTERPACE PARKWAY; BLDG C, 1ST FLOOR, PARSIPPANY NJ 07054
Vijay Aggarwal director 2320 SCIENTIFIC PARK DRIVE, WILMINGTON NC 28405
Thomas W. Burnell director, officer: President and CEO 1355 PEACHTREE STREET, SUITE 1150, ATLANTA GA 30309
Peter H Kamin 10 percent owner 2720 DONALD ROSS ROAD, #311, PALM BEACH GARDENS FL 33410
Fred S. Knechtel officer: Chief Financial Officer REMY INTERNATIONAL, INC., 600 CORPORATION DR., PENDLETON IN 46064
Fortunato R. Rocca director C/O EXAGEN INC., 1261 LIBERTY WAY, SUITE, VISTA CA 92081
Edward Chan director C/O 1315 CAPITAL II, L.P., 2929 WALNUT STREET, SUITE 1240, PHILADELPHIA PA 19104
1315 Capital Ii, L.p. 10 percent owner 2929 WALNUT STREET, SUITE 1240, PHILADELPHIA PA 19104
Robert J. Gorman director C/O INTERPACE DIAGNOSTICS GROUP, INC., 300 INTERPACE PARKWAY, PARSIPPANY NJ 07054
Laurence Mccarthy director 2110 RUTHERFORD ROAD, CARLSBAD CA 92008
Ampersand 2018 Limited Partnership 10 percent owner 55 WILLIAM STREET, SUITE 240, WELLESLEY MA 02481
Eric B. Lev director, 10 percent owner C/O INTERPACE DIAGNOSTICS GROUP, INC., 300 INTERPACE PARKWAY, PARSIPPANY NJ 07054
Thomas John Freeburg officer: Chief Accounting Officer INTERPACE DIAGNOSTICS GROUP, INC., 300 INTERPACE PKWY, BLDG. C, PARSIPPANY NJ 07054
Gregory Richard officer: Chief Commerical Officer C/O INTERPACE DIAGNOSTICS GROUP, INC., 300 INTERPACE PARKWAY, BUILDING A, PARSIPPANY NJ 07054
Felice Schnoll-sussman director C/O INTERPACE DIAGNOSTICS GROUP, INC., 300 INTERPACE PARKWAY, BUILDING A, PARSIPPANY NJ 07054

Interpace Biosciences (Interpace Biosciences) Headlines

From GuruFocus